



National Heart
Lung and Blood Institute



26TH
ANNUAL
MEETING
Los Angeles

Efficient Engraftment of Genome Edited/Modified CD34+ HSPCs in CD45 Antibody-Drug Conjugate (ADC) Conditioned Non-Human Primates


Selami Demirci, PhD



May 19, 2023

Hematopoietic stem cell transplantation

Alkylating agent (i.e., Busulfan)



Conditioning

HSCs

Stroma

Desired attribute:

Myeloablative

✓

Specificity

None

Non-genotoxic

X

Low cancer risk

X

Preserve fertility

X

Stem cells removed from donor

Patient receives treatment to destroy blood-forming cells


Donor

Blood

Stem cells


Apheresis machine

Chemotherapy



Alternative conditioning regimens

Antibody drug conjugate (i.e. CD117 or CD45)



Desired attribute:

Myeloablative ✓


Specificity **High**

Non-genotoxic ✓

Low cancer risk ✓

Preserve fertility ✓

Alkylating agent (i.e., Busulfan)



Desired attribute:

Myeloablative ✓

Specificity **None**

Non-genotoxic **X**

Low cancer risk **X**




Preserve fertility **X**




TRANSPLANTATION

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Asim Saha,¹ Sharon Hyzy,² Tahirah Lamothe,² Katelyn Hammond,² Nicholas Clark,² Leanne Lanieri,² Prashant Bhattarai,² Rahul Palchaudhuri,² Geoffrey O. Gillard,² Jennifer Proctor,² Megan J. Riddle,¹ Angela Panoskaltis-Mortari,¹ Margaret L. MacMillan,¹ John E. Wagner,¹ Hans-Peter Kiem,³ Lisa M. Olson,² and Bruce R. Blazar¹




CD45-ADC kills HSCs and immune cells *ex vivo*




HSCs: Hematopoietic stem cells, PBMCs: Peripheral blood mononuclear cells

CD45-ADC kills HSCs in cynomolgus macaques



Experimental design for edited HSPC transplantation





Demirci *et al.*, JCI, 2020
Jing *et al.*, Blood, 2021


G-CSF: Granulocyte colony stimulating factor; PBMCs: Peripheral blood mononuclear cells; SFT: Stem cell factor-thrombopoietin-fms-like tyrosine kinase 3; RBC: red blood cell; RNP: ribonucleoprotein

Partial engraftment in 0.2mg/kg CD45-ADC conditioning

Overall +58 editing (%)



15C287



Cells collected:

2.76×10^7

Transplanted viable cells:

1.56×10^7


(2.57×10^6 cells/kg)

Viability:


90%

Mock: Non-electroporated control cells, DE: Dual edited cells

Edits (PB granulocytes)






Edits (PB mononuclear cells)






Higher dose (0.3 mg/kg) CD45-ADC conditioning



13U013





13U072





	Infusion	Infusion Day post-ADC	Cell dose
13U013	0.3mg/kg - IV Bolus	Day 10	4.07×10^6 cells/kg
13U072	0.3mg/kg - IV Bolus	Day 10	1.81×10^6 cells/kg




Robust engraftment in 0.3 mg/kg CD45-ADC conditioning




Robust HbF induction in 0.3 mg/kg CD45-ADC conditioning



Indel frequencies in BM cell subsets



Barcoded HSPC transplantation experimental design




Espinoza *et al.*, *Blood*, 2017

G-CSF: Granulocyte colony stimulating factor; *PBMCs*: Peripheral blood mononuclear cells; *SFT*: Stem cell factor-fms-like tyrosine kinase 3-thrombopoietin


CD45-ADC conditioning supported polyclonal engraftment

Barcode heatmaps(Top 10 Clones)


H64K



HAWX




Shannon diversity indices of PB Gr compared across CD45-ADC, Busulfan, and TBI conditioned macaques



Conclusion

- ❑ 0.2 mg/kg CD45-ADC conditioning regimen provided partial engraftment of *BCL11A* enhancer edited HSPCs and moderate HbF induction.
- ❑ 0.3 mg/kg CD45-ADC conditioning regimen provided robust engraftment of *BCL11A* enhancer edited HSPCs and significant HbF induction.
- ❑ The CD45-ADC conditioning was able to support polyclonal HSPC engraftment, and maintain the clones for several months.
- ❑ No off-target cytotoxicity nor hematological perturbations were noted to date.

Acknowledgements



Tisdale Lab

Dr. John F. Tisdale

Dr. Robert Donahue

Dr. Naoya Uchida

Dr. Khaled Essawi

Gabriela Hinojosa

Rebecca Chu

Behroz Khan

Dr. Mathew Hsieh

Dr. Bjorg Gudmundsdottir

Dr. Alexis Leonard

Dr. Zaina Inam

Dr. Xiong Liu

Dr. Fatemeh Sheikhsaran

Jessica Peterson

Oswald Phang

Anh Le

Alexander Berg

Dunbar Lab

Dr. Cynthia E. Dunbar

Dr. Chuanfeng Wu

Dr. Taha Bartu Hayal

Diana M. Abraham



Dr. Lisa Olson

Dr. Rahul Palchaudhuri

Sharon L. Hyzy

All other members

Bauer Lab

Dr. Daniel Bauer

Dr. Jing Zeng

Anh Nguyen

Wolfe Lab

Dr. Scot Wolfe

Stacy Maitland

Flow Cytometry Core

Dr. Pradeep Dagur

Dr. Maria Lopez-Ocasio

Keyvan Keyvanfar

Animal Facility

Allen Krouse

Linde Nathaniel

Aylin Bonifacino

Justin Golomb

Theresa Engels

Sogun Hong

All other members

Biochemistry Core

Dr. Duck-Yeon Lee

selami.demirci@nih.gov